Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Amy Stark and Mary Eileen Dolan.

 
Connection Strength
 
 
 
4.068
 
  1. Stark AL, Hause RJ, Gorsic LK, Antao NN, Wong SS, Chung SH, Gill DF, Im HK, Myers JL, White KP, Jones RB, Dolan ME. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
    View in: PubMed
    Score: 0.607
  2. Stark AL, Dolan ME. Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes? Pharmacogenomics. 2013 Apr; 14(5):447-50.
    View in: PubMed
    Score: 0.566
  3. Stark AL, Delaney SM, Wheeler HE, Im HK, Dolan ME. Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet. 2012 Oct 01; 21(19):4348-55.
    View in: PubMed
    Score: 0.538
  4. Stark AL, Zhang W, Zhou T, O'Donnell PH, Beiswanger CM, Huang RS, Cox NJ, Dolan ME. Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet. 2010 Dec 10; 87(6):829-33.
    View in: PubMed
    Score: 0.481
  5. Stark AL, Zhang W, Mi S, Duan S, O'Donnell PH, Huang RS, Dolan ME. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
    View in: PubMed
    Score: 0.455
  6. Eadon MT, Hause RJ, Stark AL, Cheng YH, Wheeler HE, Burgess KS, Benson EA, Cunningham PN, Bacallao RL, Dagher PC, Skaar TC, Dolan ME. Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci. 2017 Mar 18; 18(3).
    View in: PubMed
    Score: 0.186
  7. Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52.
    View in: PubMed
    Score: 0.150
  8. Gorsic LK, Stark AL, Wheeler HE, Wong SS, Im HK, Dolan ME. EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One. 2013; 8(12):e82220.
    View in: PubMed
    Score: 0.149
  9. Eadon MT, Wheeler HE, Stark AL, Zhang X, Moen EL, Delaney SM, Im HK, Cunningham PN, Zhang W, Dolan ME. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013 Oct 01; 22(19):4007-20.
    View in: PubMed
    Score: 0.143
  10. Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013 May 23; 121(21):4366-76.
    View in: PubMed
    Score: 0.141
  11. Im HK, Gamazon ER, Stark AL, Huang RS, Cox NJ, Dolan ME. Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012 Feb; 8(2):e1002525.
    View in: PubMed
    Score: 0.131
  12. O'Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ, Dolan ME. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73.
    View in: PubMed
    Score: 0.130
  13. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
    View in: PubMed
    Score: 0.126
  14. Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ, Dolan ME. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
    View in: PubMed
    Score: 0.125
  15. Hause RJ, Stark AL, Antao NN, Gorsic LK, Chung SH, Brown CD, Wong SS, Gill DF, Myers JL, To LA, White KP, Dolan ME, Jones RB. Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am J Hum Genet. 2014 Aug 07; 95(2):194-208.
    View in: PubMed
    Score: 0.039
  16. Moen EL, Stark AL, Zhang W, Dolan ME, Godley LA. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. . 2014 May; 13(5):1334-44.
    View in: PubMed
    Score: 0.038
  17. Ko DC, Gamazon ER, Shukla KP, Pfuetzner RA, Whittington D, Holden TD, Brittnacher MJ, Fong C, Radey M, Ogohara C, Stark AL, Akey JM, Dolan ME, Wurfel MM, Miller SI. Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):E2343-52.
    View in: PubMed
    Score: 0.034
  18. Gamazon ER, Im HK, O'Donnell PH, Ziliak D, Stark AL, Cox NJ, Dolan ME, Huang RS. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. . 2011 Mar; 10(3):472-80.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.